Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (Nasdaq: CGEM) announced results from the Phase 3 REZILIENT3 trial. The provided article text does not include efficacy, safety, regulatory, or financial details, preventing an assessment of the trial’s clinical or commercial significance.